The effect of handheld-multimedia versus midazolam premedication on the level of perioperative anxiety in pediatric day-care. A randomized controlled trial.

2024-514642-37-00 Therapeutic use (Phase IV) Ongoing, recruiting

Start 31 Jan 2020 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic use (Phase IV)
Status Ongoing, recruiting
Participants planned 150
Countries 1
Sites 1

Perioperative anxiety in children scheduled for an elective circumcision, dental care or tonsillectomy/adenoidectomy in day-care

The goal of this study is, first, to evaluate the need for midazolampremedication in pediatric day-care patients induced by inhalational anesthesia, and second, to compare the efficacy and safety between anxiolysis by multimedia with an IPAD versus (no anxiolysis) and versus anxiolysis by premedication with midazolam p…

Key facts

Sponsor
UZ Brussel
Participant type
Pediatric, Patients
Age range
0-17 years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Trial duration
31 Jan 2020 → ongoing
Decision date (initial)
2024-07-10
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514642-37-00
EudraCT number
2019-004671-39

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Therapy, Safety

The goal of this study is, first, to evaluate the need for midazolampremedication
in pediatric day-care patients induced by inhalational
anesthesia, and second, to compare the efficacy and safety between
anxiolysis by multimedia with an IPAD versus (no anxiolysis) and versus
anxiolysis by premedication with midazolam prior to anestheticinduction.
Our hypothesis is that Tablet/IPAD distraction could result in equal or
better anxiety control in comparison to the standard care with
midazolam-premedication.
The primary endpoint is reduction in level of anxiety perioperative,
primarily during induction in children between one and eight years of
age in day-care-surgery.

Secondary objectives 8

  1. Anxiety reduction perioperative on daycare, holding and recovery
  2. the incidence of stressful anesthetic mask-inductions
  3. The incidence of laryngeal spasms or bronchospasm
  4. Parental satisfaction
  5. parental stress/anxiety level
  6. Postoperative anxiety
  7. Postoperative POCIS
  8. RASS-score evaluation of sedation or possible negative behavior preoperative after midazolam administration

Conditions and MedDRA coding

Perioperative anxiety in children scheduled for an elective circumcision, dental care or tonsillectomy/adenoidectomy in day-care

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 4

  1. Age ≥ 1 year and <8 years old
  2. ASA 1 or 2
  3. Elective circumcision, tonsillectomy or adenoidectomy, dental care procedure in day-care
  4. Written informed consent by the legal parents or caretaker

Exclusion criteria 14

  1. Parents of the patient wish not to participate with the study
  2. Parents are not able to give informed consent (language barrier, legally incapable)
  3. A contraindication for the use of premedication with midazolam
  4. A known allergy to midazolam
  5. A contraindication for premedication in general
  6. A contraindication for the use of a gas-induction/gas-anesthesia
  7. A contraindication for the use of sevoflurane
  8. A known mental retardation of the child
  9. Preoperative behavioral disturbances and psychiatric disorders
  10. Any use of psychoactive medication
  11. A known photosensitive epilepsy
  12. A previous operation within 3 months of the time of scheduled operation
  13. Any other contraindication for the use of the study medication
  14. Previous history of multiple surgery (>3)

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

  1. Primary endpoints are the difference in perioperative anxiety between the two groups measured with mYpas-score and parental-scoring with the 5-point anxiety scale.

Secondary endpoints 7

  1. Stressful inductions (anesthetic satisfaction) Definition of stressful anesthetic inductions will be qualified by scaling and noted by the anesthesiologist, directly post-induction. XML File Identifier: Mmsidp0h9a5a/NwZENxH2Odvq/w= Page 15/25 1. Cooperative Smooth Induction: no crying, no unrest 2. Passive induction: crying, no unrest 3. Anxious induction: crying and unrest 4. Combative induction: total hysteric 2. Parental scoring for anxiety of the patient
  2. Parental scoring for anxiety of the patient will be done by the following the 5-point anxiety scale used: 1. Happy (playing) 2. Happy/little worried (playing cautiously) 3. Worried (no playing, silently) 4. Anxious (crying) 5. Hysterical (crying and screaming) Parental scoring will be done, on the daycare preoperative, on the holding, postoperative on the recovery.
  3. Respiratory postoperative complications Scored directly post-induction and post detubation - Laryngospasm: Four-point scale (17) 1. No Laryngospasm 2. Mild laryngospasm (relieved by jaw thrust and 100% oxygen) 3. Moderate laryngospasm (relieved by 100% oxygen and positive pressure ventilation) 4. Severe laryngospasm (relieved by succinylcholine and intubation)
  4. Bronchospasm/wheezing 1. Yes 2. No • In absence of a scale
  5. Parental Satisfaction on the anxiety-management perioperative: measured on holding, after induction, recovery, postop daycare unit. 1. Extremely satisfied 2. Satisfied 3. Neutral 4. Unsatisfied 5. Extremely Unsatisfactory
  6. Postoperative POCIS-Score by leaving the recovery. POCIS is more suitable for young children then the traditional VAS-score (18) See Appendix III of the protocol
  7. Preoperative sedation or negative behavior Evaluation of sedation or possible negative behavior preoperative after midazolam is done by the RASS-score. (19) See Appendix III of the protocol

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Midazolam Rowa 2.5 mg oromucosal solution

PRD10319239 · Product

Active substance
Midazolam
Pharmaceutical form
OROMUCOSAL SOLUTION
Route of administration
ORAL USE
Max daily dose
1 mg/kg milligram(s)/kilogram
Max total dose
1 mg/kg milligram(s)/kilogram
Max treatment duration
1 Day(s)
Authorisation status
Authorised
ATC code
N05CD08 — MIDAZOLAM
Marketing authorisation
PA0074/099/001
MA holder
ROWA PHARMACEUTICALS LIMITED
MA country
Ireland
Paediatric formulation
Yes
Orphan designation
No
Modified vs. Marketing Authorisation
No

BUCCOLAM 2.5 mg oromucosal solution

PRD8810399 · Product

Active substance
Midazolam
Pharmaceutical form
OROMUCOSAL SOLUTION
Route of administration
ORAL
Max daily dose
1 mg/kg milligram(s)/kilogram
Max total dose
1 mg/kg milligram(s)/kilogram
Max treatment duration
1 Day(s)
Authorisation status
Authorised
ATC code
N05CD08 — MIDAZOLAM
Marketing authorisation
EU/1/11/709/001
MA holder
NEURAXPHARM PHARMACEUTICALS S.L.
MA country
EU
Paediatric formulation
No
Orphan designation
No
Modified vs. Marketing Authorisation
No

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

UZ Brussel

Sponsor organisation
UZ Brussel
Address
Laarbeeklaan 101
City
Jette
Postcode
1090
Country
Belgium

Scientific contact point

Organisation
UZ Brussel
Contact name
Virgini Van Buggenhout

Public contact point

Organisation
UZ Brussel
Contact name
Domien Vanhonacker

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 150 1
Rest of world 0

Investigational sites

Belgium

1 site · Ongoing, recruiting
UZ Brussel
Anesthesiology, Laarbeeklaan 101, 1090, Jette

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2020-01-31 2020-01-31

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 10 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

TypeTitleVersion
Protocol (for publication) D1_protocol_2024-514642-37-00_redacted 5
Recruitment arrangements (for publication) K1_recruitment arrangements_2024-514642-37-00_Statement_Not applicable_redacted 1
Subject information and informed consent form (for publication) L1_SIS and ICF adults FR_2024-514642-37-00_redacted 3
Subject information and informed consent form (for publication) L1_SIS and ICF adults NL_2024-514642-37-00_redacted 3
Subject information and informed consent form (for publication) L2_other subject information material GDPR FR_2024-514642-37-00_redacted 2
Subject information and informed consent form (for publication) L2_other subject information material GDPR NL_2024-514642-37-00_redacted 2
Summary of Product Characteristics (SmPC) (for publication) E2_SmPC Buccolam 1
Summary of Product Characteristics (SmPC) (for publication) E2_SmPC_Midazolam 1
Summary of Product Characteristics (SmPC) (for publication) E2_SmPC_Midazolam UK 1
Summary of Product Characteristics (SmPC) (for publication) E2_SmPC_Midazolam US 1

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-25 Belgium Acceptable
2024-07-02
2024-07-10